Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Non-Current Debt for 3 consecutive years, with $391.9 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non-Current Debt rose 8.6% year-over-year to $391.9 million; the TTM figure through Dec 2025 stood at $391.9 million (up 8.6% YoY), while the FY2025 annual figure was $391.9 million, up 14.66% from the prior year.
• Non-Current Debt grew to $391.9 million in Q4 2025 per TLX's latest filing, from $360.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $391.9 million in Q4 2025 and bottomed at $5.3 million in Q4 2023.
• Historically, Non-Current Debt has averaged $252.7 million across 3 years, with a median of $360.9 million in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Debt jumped 6652.77% — and 2025, when it rose 8.6%.
• Telix Pharmaceuticals' Non-Current Debt stood at $5.3 million in 2023, then soared by 6652.77% to $360.9 million in 2024, then gained by 8.6% to $391.9 million in 2025.
• Business Quant data shows TLX's Non-Current Debt at $391.9 million in Q4 2025, $360.9 million in Q4 2024, and $5.3 million in Q4 2023.